These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22343966)

  • 21. Contemporary management of metastatic castration-resistant prostate cancer.
    Sonpavde G; Sternberg CN
    Curr Opin Urol; 2011 May; 21(3):241-7. PubMed ID: 21455038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cabazitaxel for the treatment of prostate cancer.
    Michielsen DP; Braeckman JG; Denis L
    Expert Opin Pharmacother; 2011 Apr; 12(6):977-82. PubMed ID: 21406025
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New therapies for castration-resistant prostate cancer: efficacy and safety.
    Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
    Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
    Di Lorenzo G; Ferro M; Buonerba C
    BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improving outcomes with recent advances in chemotherapy for castrate-resistant prostate cancer.
    Sartor O; Halstead M; Katz L
    Clin Genitourin Cancer; 2010 Dec; 8(1):23-8. PubMed ID: 21208852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metastatic hormone refractory prostate cancer: recent advances in standard treatment paradigm, and future directions.
    Keizman D; Maimon N; Gottfried M
    Am J Clin Oncol; 2014 Jun; 37(3):289-96. PubMed ID: 22772426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer.
    Pal SK; Sartor O
    Asian J Androl; 2011 Sep; 13(5):683-9. PubMed ID: 21602834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing outcomes of advanced prostate cancer: drug sequencing and novel therapeutic approaches.
    Crawford ED; Flaig TW
    Oncology (Williston Park); 2012 Jan; 26(1):70-7. PubMed ID: 22393799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel therapies for metastatic castrate-resistant prostate cancer.
    Dayyani F; Gallick GE; Logothetis CJ; Corn PG
    J Natl Cancer Inst; 2011 Nov; 103(22):1665-75. PubMed ID: 21917607
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abiraterone and increased survival in metastatic prostate cancer.
    Sonpavde G
    N Engl J Med; 2011 Aug; 365(8):766-7; author reply 767-8. PubMed ID: 21864181
    [No Abstract]   [Full Text] [Related]  

  • 31. Abiraterone for the treatment of metastatic castrate-resistant prostate cancer.
    Beckett RD; Rodeffer KM; Snodgrass R
    Ann Pharmacother; 2012; 46(7-8):1016-24. PubMed ID: 22714819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Agents that target androgen synthesis in castration-resistant prostate cancer.
    Ferraldeschi R; de Bono J
    Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.
    Bazarbashi S; Bachour M; Bulbul M; Alotaibi M; Jaloudi M; Jaafar H; Mukherji D; Farah N; Alrubai T; Shamseddine A
    Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sipuleucel-T for the treatment of advanced prostate cancer.
    Frohlich MW
    Semin Oncol; 2012 Jun; 39(3):245-52. PubMed ID: 22595047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view.
    Bracarda S; Sisani M; Marrocolo F; Hamzaj A; Del Buono S; Altavilla A
    Expert Rev Anticancer Ther; 2014 Nov; 14(11):1283-94. PubMed ID: 25353258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A renaissance in the medical treatment of advanced prostate cancer.
    Rove KO; Flaig TW
    Oncology (Williston Park); 2010 Dec; 24(14):1308-13, 1318. PubMed ID: 21294475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging therapies in castrate-resistant prostate cancer.
    Lassi K; Dawson NA
    Curr Opin Oncol; 2009 May; 21(3):260-5. PubMed ID: 19363343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metastatic castrate-resistant prostate cancer: dawn of a new age of management.
    Masson S; Bahl A
    BJU Int; 2012 Oct; 110(8):1110-4. PubMed ID: 22564337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer.
    Francini E; Fiaschi AI; Petrioli R; Francini F; Bianco V; Perrella A; Paganini G; Laera L; Roviello G
    Anticancer Drugs; 2014 Apr; 25(4):472-7. PubMed ID: 24394473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients.
    Attard G; de Bono JS
    Clin Cancer Res; 2011 Jun; 17(12):3867-75. PubMed ID: 21680542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.